Aditxt, Inc. 8-K
Research Summary
AI-generated summary
Aditxt, Inc. Receives Nasdaq Delisting Notice Over Equity Deficit
What Happened
- Aditxt, Inc. (ADTX) reported stockholders’ equity of $(35,174,386) in its Form 10-Q for the quarter ended March 31, 2026. On May 27, 2026 Nasdaq’s Listing Qualifications Staff sent a letter notifying the company it no longer meets the $2,500,000 minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market and that this equity shortfall is an additional basis for delisting.
- The company previously received a delisting determination on May 6, 2026 for failure to meet Nasdaq’s minimum bid price rule; Aditxt timely requested a hearing, which is scheduled for June 11, 2026, and plans to present its remediation plan at that Hearing.
Key Details
- Stockholders’ equity reported: $(35,174,386) (Form 10-Q for period ended March 31, 2026).
- Nasdaq minimum stockholders’ equity requirement: $2,500,000 (Rule 5550(b)(1)); alternatives (not met) include $35M market value or $500,000 net income.
- Prior action: May 6, 2026 delisting determination for minimum bid price; company appealed and Hearing set for June 11, 2026.
- Additional noncompliance: company believes it does not meet the $1,000,000 Market Value of Publicly Held Shares requirement (MVPHS), though Nasdaq has not yet issued a deficiency notice on that point.
Why It Matters
- If the Nasdaq Hearings Panel upholds delisting, Aditxt’s common stock could be removed from The Nasdaq Capital Market, which the filing says would materially reduce liquidity and market price and make raising capital more difficult.
- The filing warns these conditions raise substantial doubt about the company’s ability to continue as a going concern and, without adequate working capital, operations could be discontinued — outcomes that could cause investors to lose their entire investment.
- The company will present its case and plans to regain compliance at the Hearing, but the Panel has broad discretion and there is no assurance of a favorable outcome or additional cure period.
Loading document...